CAI
Caris Life Sciences, Inc.
32.30$
+2.0%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q2 21 | Q3 21 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 50.0% | 46.4% | 67.6% | 62.5% | 56.3% | 45.6% | 52.8% | 37.3% | 32.0% | 24.6% | 34.6% | 31.9% | 30.3% | |
| 100.0% | 53.6% | 32.4% | 37.5% | 43.7% | 54.4% | 47.2% | 62.7% | 68.0% | 75.4% | 65.4% | 68.1% | 69.7% | |
| – | – | 42.6% | 24.8% | 27.2% | 20.9% | 19.1% | 13.8% | 10.0% | 10.9% | 2.5% | 12.3% | 9.2% | |
| 11.9% | 12.2% | 56.4% | 41.0% | 40.2% | 28.0% | 44.1% | 35.5% | 24.0% | 19.3% | 27.6% | 25.2% | 23.7% | |
| 40.7% | 12.2% | 146.7% | -29.4% | 103.6% | 82.9% | 95.1% | 52.8% | 53.0% | 45.2% | 62.9% | 57.9% | 54.2% | |
| 59.3% | 65.9% | -114.3% | 67.0% | -59.9% | -28.5% | -47.9% | 9.9% | 15.1% | 30.2% | 2.4% | 10.2% | 15.5% | |
| 13.0% | – | 11.5% | 13.7% | 13.6% | 10.2% | 10.6% | 10.6% | 6.2% | 3.9% | 5.9% | 3.5% | 4.7% | |
| 46.4% | 54.4% | -137.6% | -66.2% | -66.6% | -28.4% | -84.8% | -39.6% | 11.2% | 28.0% | -0.3% | -0.2% | 10.6% | |
| 2.2% | 3.6% | – | – | – | – | – | – | – | – | -0.1% | 0.0% | – | |
| 44.3% | 50.7% | -137.6% | -66.2% | -66.6% | -28.4% | -84.8% | -39.6% | 11.2% | 28.0% | -0.2% | -0.2% | 10.6% | |
| 59.4% | 87.0% | -104.2% | -40.9% | -49.5% | -21.5% | -68.4% | -25.5% | 19.7% | 33.3% | 8.0% | 5.7% | 17.5% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.